Skip to content
Head to head

Alvotech vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: ALVO · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

ALVO -19.8%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
ALVOTAK
Snapshot
Sector----
Last price4.1221.77
Change today-3.96%+1.68%
1-year return-18.6%+57.5%
Market cap$1.47B$69.76B
52-week range2.94 – 6.5313.92 – 22.07
Valuation
P/E (TTM)-5.02311.00
P/E percentile, own 5-yr range50th100th
P/B-5.501.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)0.10-0.30
Net profit (TTM)$35.68M$-970.94M
Revenue (TTM)$491.95M$4.69T
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)-38.9%+6.7%
Gross margin56.8%65.8%
Operating margin12.1%14.3%
Net margin-50.9%0.9%
Free cash flow (TTM)$-333.82M$433.95B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership72.5%51.3%
Insider activity (12mo)0 buy / 0 sell19 buy / 31 sell
Short interest (% of float)1.7%0.1%
Analyst consensus100% buy (4)100% buy (1)
Analyst price target$8 (+94%)$50 (+132%)
StockVane view
StockVane Quant RatingD (19)C (90)
Company
Employees1,46047,029
Founded20131781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.